Table 1.
Characteristics of reports with suspected HSRs sourced from VigiBase
| Gadopentetate dimeglumine | Gadobenate dimeglumine | Gadoxetate disodium | Gadoterate meglumine | Gadodiamide | Gadoversetamide | Gadoteridol | Gadobutrol | ||
|---|---|---|---|---|---|---|---|---|---|
| Total | 5160 | 3653 | 1250 | 6489 | 1064 | 323 | 2997 | 9454 | |
| Gender | F | 3005 (58.24%) | 2202 (60.28%) | 521 (41.68%) | 4123 (63.54%) | 579 (54.42%) | 120 (37.15%) | 1842 (61.46%) | 5737 (60.68%) |
| M | 1800 (34.88%) | 1275 (34.90%) | 551 (44.08%) | 2188 (33.72%) | 336 (31.58%) | 70 (21.67%) | 1046 (34.90%) | 3202 (33.87%) | |
| Unknown | 3556.88%) | 176 (4.82%) | 178 (14.24%) | 178 (2.74%) | 149 (14.00%) | 133 (41.18%) | 109 (3.64%) | 515 (5.45%) | |
| Age | 0–27 days | 1 (0.02%) | 3 (0.08%) | 0 (0%) | 5 (0.08%) | 0 (0%) | 0 (0%) | 3 (0.10%) | 13 (0.14%) |
| 28 days–23 months | 8 (0.16%) | 1 (0.03%) | 0 (0%) | 11 (0.17%) | 2 (0.19%) | 0 (0%) | 1 (0.03%) | 7 (0.07%) | |
| 2–11 years | 85 (1.65%) | 12 (0·33%) | 2 (0.16%) | 130 (2.00%) | 7 (0.66%) | 1 (0.31%) | 23 (0.77%) | 65 (0.69%) | |
| 12–17 years | 138 (2.67%) | 60 (1.64%) | 2 (0.16%) | 199 (3.07%) | 27 (2.54%) | 1 (0.31%) | 58 (1.94%) | 205 (2.17%) | |
| 18–44 years | 1852 (35.89%) | 1097 (30.03%) | 198 (15.84%) | 2251 (34.69%) | 319 (29.98%) | 55 (17.03%) | 991 (33.07%) | 2903 (30.71%) | |
| 45–64 years | 1680 (32.56%) | 1331 (36.44%) | 584 (46.72%) | 2386 (36.77%) | 323 (30.36%) | 57 (17.65%) | 1144 (38.17%) | 3725 (39.40%) | |
| 65–74 years | 461 (8.93%) | 452 (12.37%) | 188 (15.04%) | 638 (9.83%) | 91 (8.55%) | 11 (3.41%) | 348 (11.61%) | 1119 (11.84%) | |
| ≥ 75 years | 214 (4.15%) | 207 (5.67%) | 66 (5.28%) | 248 (3.82%) | 39 (3.67%) | 6 (1.86%) | 155 (5.17%) | 409 (4.33%) | |
| Unknown | 721 (13.97%) | 490 (13.41%) | 210 (16.80%) | 621 (9.57%) | 256 (24.06%) | 192 (59.44%) | 274 (9.14%) | 1008 (10.66%) | |
| UN Continent | Americas | 3404 (65.97%) | 1678 (45.93%) | 227 (18.16%) | 787 (12.13%) | 590 (55.45%) | 312 (96.59%) | 674 (22.49%) | 2321 (24.55%) |
| Asia | 761 (14.75%) | 466 (12.76%) | 870 (69.60%) | 2217 (34.17%) | 149 (14.00%) | 8 (2.48%) | 820 (27.36%) | 4152 (43.92%) | |
| Europe | 899 (17.42%) | 1460 (39.97%) | 138 (11.04%) | 3381 (52.09%) | 278 (26.13%) | 2 (0.62%) | 1503 (50.15%) | 2681 (28.36%) | |
| Oceania | 89 (1.72%) | 47 (1.29%) | 14 (1.12%) | 100 (1.54%) | 41 (3.85%) | 1 (0.31%) | 0 (0%) | 289 (3.06%) | |
| Africa | 7 (0.14%) | 2 (0.05%) | 1 (0.08%) | 5 (0.08%) | 6 (0.56%) | 0 (0%) | 0 (0%) | 11 (0.12%) | |
| Years of reporting | 2022 | 93 (1.80%) | 89 (2.44%) | 42 (3.36%) | 523 (8.06%) | 23 (2.16%) | 0 (0%) | 204 (6.81%) | 599 (6.34%) |
| 2021 | 101 (1.96%) | 105 (2.87%) | 95 (7.60%) | 684 (10.54%) | 13 (1.22%) | 0 (0%) | 316 (10.54%) | 882 (9.33%) | |
| 2020 | 93 (1.80%) | 247 (6.76%) | 137 (10.96%) | 632 (9.74%) | 20 (1.88%) | 0 (0%) | 408 (13.61%) | 908 (9.60%) | |
| 2019 | 203 (3.93%) | 286 (7.83%) | 241 (19.28%) | 794 (12.24%) | 148 (13.91%) | 4 (1.24%) | 362 (12.08%) | 1002 (10.60%) | |
| 2018 | 71 (1.38) | 173 (4.74%) | 111 (8.88%) | 880 (13.56%) | 23 (2.16%) | 10 (3.10%) | 349 (11.64%) | 1153 (12.20%) | |
| 2017 | 87 (1.69%) | 242 (6.62%) | 102 (8.16%) | 540 (8.32%) | 29 (2.73%) | 3 (0.93%) | 187 (6.24%) | 888 (9.39%) | |
| 2016 | 93 (1.80%) | 276 (7.56%) | 75 (6.00%) | 373 (5.75%) | 37 (3.48%) | 8 (2.48%) | 162 (5.41%) | 736 (7.79%) | |
| 2015 | 152 (2.95%) | 291 (7.97%) | 97 (7.76%) | 403 (6.21%) | 56 (5.26%) | 12 (3.72%) | 82 (2.74%) | 773 (8.18%) | |
| 2014 | 214 (4.15%) | 473 (12.95%) | 105 (8.40%) | 429 (6.61%) | 41 (3.85%) | 5 (1.55%) | 103 (3.44%) | 648 (6.85%) | |
| 2013 | 99 (1.92%) | 113 (3.09%) | 53 (4.24%) | 140 (2.16%) | 26 (2.44%) | 2 (0.62%) | 70 (2.34%) | 335 (3.54%) | |
| 2012 | 276 (5.35%) | 140 (3.83%) | 48 (3.84%) | 135 (2.08%) | 42 (3.95%) | 11 (3.41%) | 55 (1.84%) | 382 (4.04%) | |
| 2011 | 360 (6.98%) | 194 (5.31%) | 31 (2.48%) | 155 (2.39%) | 86 (8.08%) | 31 (9.60%) | 66 (2.20%) | 232 (2.45%) | |
| 2010 | 385 (7.46%) | 174 (4.76%) | 15 (1.20%) | 79 (1.22%) | 76 (7.14%) | 39 (12.07%) | 93 (3.10%) | 117 (1.24%) | |
| 2009 | 557 (10.79%) | 177 (4.85%) | 8 (0.64%) | 32 (0.49%) | 93 (8.74%) | 59 (18.27%) | 100 (3.34%) | 49 (0.52%) | |
| 2008 | 295 (5.72%) | 475 (13.00%) | 1 (0.08%) | 70 (1.08%) | 58 (5.45%) | 10 (3.10%) | 98 (3.27%) | 42 (0.44%) | |
| Outcome | Death | 55 (1.07%) | 45 (1.23%) | 0 (0.00%) | 14 (0.22%) | 32 (3.01%) | 22 (6.81%) | 30 (1.00%) | 50 (0.53%) |
| Life-threatening | 154 (2.98%) | 268 (7.34%) | 17 (1.36%) | 241 (3.71%) | 30 (2.82%) | 3 (0.93%) | 186 (6.21%) | 257 (2.72%) | |
| Disability | 24 (0.47%) | 15 (0.41%) | 1 (0.08%) | 13 (0.20%) | 28 (2.63%) | 13 (4.02%) | 14 (0.47%) | 27 (0.29%) | |
| Hospitalization | 231 (4.48%) | 509 (13.93%) | 32 (2.56%) | 507 (7.81%) | 50 (4.70%) | 24 (7.43%) | 330 (11.01%) | 589 (6.23%) | |
| Other | 4696 (91.01%) | 2816 (77.09%) | 1200 (96.00%) | 5714 (88.06%) | 924 (86.84%) | 261 (80.80%) | 2437 (81.31%) | 8531 (90.24%) | |
| Reported rate of serious events | 8.99% | 22.91% | 4.00% | 11.94% | 13.16% | 19.2% | 18.69% | 9.26% |
HSR hypersensitivity reactions, UN United Nations